BIOMARKERS FOR THE DIAGNOSIS AND CHARACTERIZATION OF ALZHEIMER'S DISEASE

Embodiments of the present disclosure relate generally to the analysis and identification of global metabolic changes in Alzheimer's disease (AD). More particularly, the present disclosure provides materials and methods relating to the use of metabolomics as a biochemical approach to identify p...

Full description

Saved in:
Bibliographic Details
Main Authors KADDURAH-DAOUK, Rima F, ARNOLD, Matthias, BAILLIE, Rebecca, A, HAN, Xianlin, NHO, Kwangsik, THOMPSON, Will, ST. JOHN-WILLIAMS, Lisa, DORAISWAMY, Pudugramam, Murali, MOSELEY, M., Arthur, KOAL, Therese, SAYKIN, Andrew, J, KASTEMULLER, Gabi, TOLEDO, Jon, B
Format Patent
LanguageEnglish
French
German
Published 29.07.2020
Subjects
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Online AccessGet full text

Cover

More Information
Summary:Embodiments of the present disclosure relate generally to the analysis and identification of global metabolic changes in Alzheimer's disease (AD). More particularly, the present disclosure provides materials and methods relating to the use of metabolomics as a biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance. Defining metabolic changes during AD disease trajectory and their relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.
Bibliography:Application Number: EP20170849682